1131737-04-6

Basic information

• Product Name: CyclopropaneMethanaMine, α-(trifluoroMethyl)-, (αR)-
• Synonyms: CyclopropaneMethanaMine, α-(trifluoroMethyl)-, (αR)-;(alphaR)-alpha-(Trifluoromethyl)cyclopropanemethanamine;(1S)-1-CYCLOPROPYL-2,2,2-TRIFLUOROETHYLAMINE;(1R)-1-CYCLOPROPYL-2,2,2-TRIFLUOROETHYLAMINE hcl salt;(1R)-1-Cyclopropyl-2,2,2-trifluoroethylamine
• CAS NO: 1131737-04-6
• Molecular Formula: C5H8F3N
• Molecular Weight: 139.12
• EINECS: -0
• Mol File: 1131737-04-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 125.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.277±0.06 g/cm3(Predicted)
• PKA: 5.71±0.50(Predicted)
• CAS DataBase Reference: CyclopropaneMethanaMine, α-(trifluoroMethyl)-, (αR)-(CAS DataBase Reference)
• NIST Chemistry Reference: CyclopropaneMethanaMine, α-(trifluoroMethyl)-, (αR)-(1131737-04-6)
• EPA Substance Registry System: CyclopropaneMethanaMine, α-(trifluoroMethyl)-, (αR)-(1131737-04-6)

Safety Data

• Hazardous Substances Data: 1131737-04-6(Hazardous Substances Data)

Relevant articles and documents

IMIDAZO [1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted imidazo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted imidazo[1,5-a]pyrimidinyl carboxamide compounds described herein include substituted 2-heterocyclyl-4-alkyl-imidazo[1,5-a]pyrirnidine-8-carboxamide compounds and variants thereof.

PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.